Endobronchial valve treatment improves chest-CT diaphragm configuration in COPD

Respir Med. 2024 Nov-Dec:234:107856. doi: 10.1016/j.rmed.2024.107856. Epub 2024 Nov 6.

Abstract

This study investigated the impact of bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) on diaphragm configuration. We successfully analyzed the diaphragm index using a newly developed quantitative computed tomography (QCT) tool before and after EBV treatment in forty patients with severe emphysema. We evaluated whether changes in the diaphragm index were associated with improvements in forced expiratory volume in 1 s (FEV1), residual volume (RV), Saint Georges Respiratory Questionnaire (SGRQ), and 6-min walking distance (6MWD) using Spearman's rho. The EBV treatment influenced the diaphragm configuration only on the treated side, resulting in an increased diaphragm curvature. There were significant associations of relative diaphragm index changes on the treated lung side or the entire diaphragm with improvements in FEV1 and 6MWD. These findings provide valuable insights into how EBV treatment affects the diaphragm in COPD patients.

Trial registration: ClinicalTrials.gov NCT02025205 NCT02022683 NCT01796392 NCT02815683.

MeSH terms

  • Aged
  • Bronchoscopy* / methods
  • Diaphragm* / diagnostic imaging
  • Diaphragm* / physiopathology
  • Female
  • Forced Expiratory Volume / physiology
  • Humans
  • Male
  • Middle Aged
  • Pneumonectomy / methods
  • Pulmonary Disease, Chronic Obstructive* / diagnostic imaging
  • Pulmonary Disease, Chronic Obstructive* / physiopathology
  • Pulmonary Emphysema / diagnostic imaging
  • Pulmonary Emphysema / physiopathology
  • Pulmonary Emphysema / surgery
  • Residual Volume
  • Tomography, X-Ray Computed* / methods
  • Treatment Outcome
  • Walk Test

Associated data

  • ClinicalTrials.gov/NCT02025205
  • ClinicalTrials.gov/NCT02022683
  • ClinicalTrials.gov/NCT01796392
  • ClinicalTrials.gov/NCT02815683